Create your Personal Health Record and unlock support built around you

Aligned with your diagnosis, treatment and where you are in your care. It lets HealthTree show you:

Treatments and trials you qualify for
Education for your stage of care
Financial support for your medications
Solutions to your side effects

Learn more about HealthTree

Video

What are the most common JAK2 inhibitors used in myelofibrosis treatment?

Posted by

HealthTree

• October 29, 2025

Description

Explore the most commonly used JAK2 inhibitors in myelofibrosis treatment, including ruxolitinib, fedratinib, pacritinib, and momelotinib, and learn how they help manage the disease.

On this video

Andrew Srisuwananukorn, MD

Transcript

What are the most common JAK2 inhibitors used in myelofibrosis treatment?

We are in a golden age right now for novel therapeutics in myelofibrosis, particularly when considering the JAK2 inhibitors. Thankfully, we have a number of JAK2 inhibitors that are approved by the United States Food and Drug Administration. These include ruxolitinib, fedratinib, pacritinib, momelotinib. The most common JAK2 inhibitor that we use in clinical practice is likely to be ruxolitinib, which was the first JAK inhibitor to be approved in 2011. Patients typically start on ruxolitinib in the front line, barring some specific unique situations where the other JAK inhibitors could be very helpful.

Related Content